In her coverage of the latest global medical trends, Dr. Azza Ibrahim highlights the groundbreaking discussions from the recent Aging and Drug Research Conference in Copenhagen. The focus has shifted from seeing GLP-1 agonists (like Semaglutide and Tirzepatide) merely as weight-loss tools to recognizing them as key players in Longevity and healthspan extension.
Beyond Weight Loss: The Multi-Organ Benefits of GLP-1: Current research indicates that GLP-1 therapies offer far-reaching systemic advantages:
- Cardiovascular Protection: Significant support for heart and vascular health.
- Metabolic Excellence: Enhancing liver function and optimizing metabolic pathways.
- Anti-Inflammatory Properties: Reducing chronic low-grade inflammation, a primary driver of aging.
- Neurological & Mental Health: Potential in preventing dementia, memory decline, and improving mood disorders like depression.
Event Videos
